Syneos Health, Inc. (NASDAQ:SYNH) Analyst Consensus Recommendation of “Hold”

Syneos Health, Inc. (NASDAQ: SYNH – Get Rating) shares have received an average rating of “Hold” from the thirteen ratings firms that cover the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The 12-month average target price among brokers who covered the stock over the past year is $51.11.

Numerous analysts have commented on SYNH shares. Barclays cut its price target on Syneos Health shares from $60.00 to $30.00 and set an “overweight” rating for the company in a report on Sunday, Nov. 6. Robert W. Baird lowered his price target on Syneos Health shares from $80.00 to $42.00 and set an “outperform” rating for the company in a research report on Monday, Nov. 7. StockNews.com has taken over coverage of Syneos Health stock in a research report Wednesday, Oct. 12. They set a “hold” rating for the company. JPMorgan Chase & Co. cut Syneos Health’s shares from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $85.00 to $53.00 in a research report Tuesday 18 October. Finally, on Wednesday, September 14, Guggenheim cut Syneos Health’s shares from a “buy” rating to a “neutral” rating.

Institutional investors weigh on Syneos Health

Hedge funds and other institutional investors have recently changed their holdings in the company. Eagle Asset Management Inc. acquired a new stake in Syneos Health during the second quarter for $46,487,000. Cooke & Bieler LP increased its position in Syneos Health by 20.2% during the second quarter. Cooke & Bieler LP now owns 2,836,728 shares of the company valued at $203,337,000 after purchasing an additional 477,225 shares during the most recent quarter. Macquarie Group Ltd. increased its position in Syneos Health by 69.9% during the third quarter. Macquarie Group Ltd. now owns 1,151,572 shares of the company valued at $54,351,000 after purchasing an additional 473,794 shares during the most recent quarter. Assenagon Asset Management SA increased its position in Syneos Health by 522.6% during the third quarter. Assenagon Asset Management SA now owns 497,456 shares of the company valued at $23,455,000 after purchasing an additional 417,559 shares during the recent quarter. Finally, AQR Capital Management LLC increased its position in Syneos Health by 86.8% during the second quarter. AQR Capital Management LLC now owns 803,538 shares of the company valued at $57,598,000 after purchasing an additional 373,351 shares during the most recent quarter. 93.51% of the stock is currently owned by institutional investors and hedge funds.

Syneos Health shares down 1.4%

SYNH opened at $34.93 on Friday. Syneos Health has a twelve-month low of $22.89 and a twelve-month high of $95.68. The company has a quick ratio of 1.14, a current ratio of 1.14, and a debt-to-equity ratio of 0.84. The company has a 50-day moving average price of $35.41 and a 200-day moving average price of $52.53. The company has a market cap of $3.59 billion, a PE of 12.70, and a beta of 1.63.

About Syneos Health

(Get Rating)

Syneos Health, Inc provides biopharmaceutical outsourcing solutions companies in North America, Europe, Middle East, Africa, Asia-Pacific and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapies in Phase I through IV of clinical development.

Featured Articles

Analyst Recommendations for Syneos Health (NASDAQ:SYNH)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before you consider Syneos Health, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are whispering to their customers to buy now before the broader market catches on…and Syneos Health wasn’t on the list.

While Syneos Health currently has a “Hold” rating among analysts, senior analysts believe these five stocks are better buys.

View the five titles here

Investment strategies to help grow your retirement income coverage

Leave a Comment

Your email address will not be published. Required fields are marked *